<DOC>
	<DOCNO>NCT02395926</DOCNO>
	<brief_summary>Choline alfoscerate ( L-alfa glycerylphosphorylcholine ) natural compound find brain breast . Choline alfoscerate contain 40.8 % choline produrig structure separate precursor choline nerve cell membrane precursor acetylcholine glycerophosphate . Choline alfoscerate Colin normalization nerve pathway , nerve cell membrane play acetylcholine receptor function secondary symptom cause cerebrovascular deficiency indirectly activation metabolism , degenerative effect brain organic mental syndrome . Currently market oral choline alfoscerate receive geriatric cognitive impairment , secondary symptom degeneration , soft capsule authorize prescription drug degenerative brain organic mental syndrome cause cerebrovascular deficiency . Gliatilin soft capsule contain 400 mg per 1 capsule 2-3 time one day 're suppose take consider optimal convenience efficiency drug patient development sustain release formulation maintain long period time , certain concentration require . Accordingly , modern drug reduce frequency administration day circuit develop sustain release formulation choline alfoscerate HT-003 600 mg medication compliance purpose raise . 2 tablet time ( 600 mg x 2 ) take one day 1200 mg require taking . Therefore , development sustain release formulation , test healthy adult male volunteer target choline alfoscerate soft capsule formulation 400mg 3 time per 1 day sustained-release tablet 600mg 2time per 1 day , pharmacokinetic property safety single dose evaluate compare .</brief_summary>
	<brief_title>To Evaluate Safety Pharmacokinetic Characteristics After Oral Administration HT-003 Compared With Choline Alfoscerate Capsule Healthy Adult Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Choline</mesh_term>
	<criteria>1 . Healthy male subject age 20 55 year , inclusive 2 . BMI &gt; =19kg/m2 , &lt; =27kg/m2 *body mass index ( kg/m2 ) = weight ( kg ) / [ ( height ( ) 2 ) 3 . Voluntary write consent party ability willingness participate entire period test 1 . Subjects history clinically significant disease liver , kidney , digestive , respiratory , musculoskeletal , endocrine , neuropsychiatric , blood•tumor type , cardiovascular disease . 2 . A GFR le 60ml/min person , calculate MDRD ( Modification Diet Renal Disease ) ※ MDRD equation ( mL/min/1.73m2 ) : GFR = 175 x Scr1.154 x age0.203 3 . Systolic blood pressure le 90 mmHg vital sign 150 mmHg diastolic blood pressure le 50 mmHg high numerical character show equal least 100 mmHg 4 . Subjects know hypersensitivity reaction component investigational drug 5 . Subjects history drug abuse , show positive urine drug screen test 6 . Use prescription medication within 14 day prior study medication dosing use medication overthecounter medication include oriental medication within 7 day prior study medication dose 7 . Participation clinical investigation within 60days prior study medication dose 8 . Subjects whole blood donation within 60days , component blood donation within 30days 9 . Caffeinecontaining beverage ( coffee , tea , cola ) intake grapefruit / orange juice exceed average daily intake 4 cup . 10 . Subjects intake average alcohol consumption per week exceeds 140g nonalcohol hospital stay . 11 . Subjects exceed average daily smoke 10 cigarette nonsmoking hospital stay 12 . Subjects limit cholinecontaining food ( liver , cocoa , bean , chocolate , otmil etc ) , admitted hospital day 13 . Subjects show positive serum test ( hepatitis B , C , HIV ) 14 . Subjects decision nonparticipation investigator 's review due laboratory test result excuse nonresponding request instruction investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>